MARKET NEWS

Upstream Plasma Extraction is Stagnant and Demand Outstrips Supply of Global Intravenous Immunoglobulin Market

Intravenous immunoglobulin refers to the globulin which is specially prepared for intravenous infusion by precipitation and reprocessing of the components extracted from the plasma of healthy people by low-temperature ethanol method to remove the anti-complement activity and inactivate virus by Pasteurization.

There are five types of immunoglobulins, including IgG, IgA, IgM, IgD and IgE. IgG antibody is a kind of globulin with antibody-like structure or antibody activity, which is the antibody of the re-immune response and the most important anti-pathogen microbial antibody in body fluids. It is the only immunoglobulin that can cross the placental barrier and neutralizes toxins and viruses. If the body is found to have antibodies to a disease, it can avoid the infection of the disease, the disease has immunity. For COVID-19, a positive IgG antibody indicates a history of infection with the virus. 

Intravenous immunoglobulin can be divided into liquid preparations and powders. At present, immunoglobulin liquid preparations are more widely used, which accounted for 86.75% of the market in 2020, while powder only accounted for 13.25% of the market. Immunoglobulin liquid preparation can enhance the immune power of human body and have the effect of resistance to viruses, bacteria and other microorganisms.While working with antibiotic, antiviral and antifungal drug use, they can enhance the effect of these drugs, improve the body IgG levels of patients and can treat primary immune globulin deficiency, secondary immunoglobulin defects,  such as severe infection, sepsis, autoimmune diseases, including primary thrombocytopenic purpura, autoimmune anemia and so on. 

Status Analysis and Forecast of Global Intravenous Immunoglobulin Market

North America is global largest market for intravenous immunoglobulin by revenue, accounting for more than half of the global market.In 2020,market share of North America  in the industry was 60.99%, but its market share is expected to decline over the forecast period to 60.35% by 2025. Europe and Asia Pacific ranked second and third with 22.64% and 14.54% market share respectively, while South America, the Middle East and Africa had a very low market share of 1.10% and 0.73% respectively. Asia Pacific is expected to be the fastest-growing market in the industry as its market share increases year by year and is expected to continue to expand throughout the year. By 2025, Asia Pacific\'s market share in the global intravenous immunoglobulin industry is expected to grow to 15.73%. 

The top three companies are CSL Behring, Grifols and Octapharma from Switzerland, the US and Australia respectively. CSL Behring is a company that develops, manufactures and markets protein-based therapeutics for hemorrhagic diseases, fluid rehydration, hereditary angioedema, immunoglobulin, lung and wound healing plasma derived and recombinant therapies. Grifols develops, manufactures and markets plasma derivatives, intravenous therapies, enteral nutrition, diagnostic systems and medical materials. Octapharma develops, manufactures and markets drugs derived from human proteins. The company provides biopharmaceutical products and therapeutics for hematology, critical care and emergency medicine, and immunotherapy. In 2020, the three companies accounted for 16.75%, 8.74% and 5.06% of the global intravenous immunoglobulin market,respectively. The total market share of the top three companies is 30.55%, and the industry concentration is not high.

View the full TOC at: https://www.globalmarketmonitor.com/reports/762630-intravenous-immunoglobulin-(ivig)-market-report.html

Research data show that the global market value of immunoglobulin for intravenous injection was $5.393 billion in 2015. The industry developed rapidly from 2015 to 2020, and the market value reached $10.346 billion in 2020. Based on this data, and combined with the industry development law, we carried out a series of function operations, scientific derivation of the next five years of data. Finally, it is predicted that the annual value of the global injective immunoglobulin industry will continue to rise in 2021-2025, and will grow to $20.09 billion in 2025, with a CAGR of 9.70% in 2021-2025. 

Public Awareness of Health Management Has Been Strengthened; Upstream Plasma Extraction Is Stagnant and Demand Outstrips Supply of Global Intravenous Immunoglobulin Market

In 2020, the development of many industries slowed down or stagnated due to the COVID-19 pandemic, but the pandemic has boosted the development of the global intravenous immunoglobulin industry to a certain extent. Data showed that the total market value of the industry in 2020 was $10.346 billion, an increase of $2.221 billion and 21.47%, compared with 2019. Immunity is a very important condition for combating the COVID-19 epidemic.Through the outbreak, public awareness of early treatment, treatment and disease prevention has increased significantly. There will also be a higher demand for health management and medical care after the end of the epidemic, which will promote the growth of medical consumption and open up the market from the demand side. In addition, people have a deeper understanding of the prognosis and harm of the disease, and the research and development of related drugs and reagents will certainly receive more attention.This will bring more attention to the intravenous immunoglobulin (IVIg) industry, spur product innovation and development, and energize the market, as more pharmaceutical companies are expected to step up research and development and manufacturing of these drugs. 

However, the epidemic has now resulted in a virtual suspension of plasma donation at plasma collection stations worldwide. Due to the quarantine period, stored plasma must be re-qualified after 3 months before it can be put into production. If the epidemic prevention and control situation in Europe and the United States continues to be unclear, it will become more difficult to resume the extraction of plasma, which will lead to a shortage of plasma supply. In this situation, the price of IVIg products for intravenous injection is expected to rise rapidly in the short term. 

Facing the impact of COVID-19, mature chronic disease drugs such as Intravenous Immunoglobulin (IVIg) have used changes in the prescription mechanism (a three-month long-term prescription can be issued at a time) to change sales channels and successfully reduce the significant impact of the epidemic , to help the industry quickly recover from the negative impact of the epidemic.Overall, the pharmaceutical market is relatively strong. At the same time, with the continuous opening of the hospital, the confidence of patients gradually enhanced after recovery, the market will gradually pick up. 

View the full TOC at: https://www.globalmarketmonitor.com/reports/762630-intravenous-immunoglobulin-(ivig)-market-report.html